Hannah Valantine bought $30k of BBIO
director at BridgeBio Pharma, Inc.. 2,338 shares at an average of $12.84, traded Dec 28, 2021, filed Jun 30, 2025.
Score components
- +15RoleDirector
- +5Trade size$30k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-091756, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 28, 2021 | POpen-market purchase Common Stock | +1,542 | $12.68 | $20k | 1,542 | Jun 30, 2025 |
| Dec 28, 2021 | POpen-market purchase Common Stockindirect: By Spouse | +796 | $13.16 | $10k | 2,687 | Jun 30, 2025 |
Related signals
Other insiders at BridgeBio Pharma, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 26Weak | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $691k 10,000 shares | -2% | |
| 50Moderate | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $5.5M 80,000 shares | -12% | |
| 35Weak | BridgeBio Pharma, Inc. | Hannah Valantine director | $624k 8,671 shares | -54% | |
| 40Moderate | BridgeBio Pharma, Inc. | Andrea Ellis director | $4.2M 64,921 shares | -78% | |
| 40Moderate | BridgeBio Pharma, Inc. | Hannah Valantine director | $1.7M 25,484 shares | -77% | |
| 21Weak | BridgeBio Pharma, Inc. | Maricel Apuli Chief Accounting Officer | $132k 2,000 shares | -2% | |
| 50Moderate | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $2.0M 28,053 shares | -11% | |
| 16Weak | BridgeBio Pharma, Inc. | Maricel Apuli Chief Accounting Officer | $38k 510 shares | -0% | |
| 27Weak | BridgeBio Pharma, Inc. | Randal W. Scott director | $755k 10,000 shares | -46% | |
| 42Moderate | BridgeBio Pharma, Inc. | Thomas Trimarchi President and CFO | $1.0M 13,600 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.